In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), with a price target of $36.00. The company’s shares closed last Tuesday at $21.56.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 17.9% and a 42.3% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Seres Therapeutics with a $37.25 average price target.
Seres Therapeutics’ market cap is currently $1.86B and has a P/E ratio of -18.70. The company has a Price to Book ratio of 10.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.